Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir

AIDS

Volumn 26, Issue 5, 2012, Pages 551-557

  Garrido, Carolina ^a   Rallón, Norma ^a   Soriano, Vincent ^a   Lopez, Mariola ^a   Zahonero, Natalia ^a   De Mendoza, Carmen ^a   Benito, Jose M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Apoptosis; HIV; Immune response; Raltegravir; Thymopoiesis

Indexed keywords

ATAZANAVIR; CD27 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; LOPINAVIR; RALTEGRAVIR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; 2 PYRROLIDONE DERIVATIVE; CD31 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; INTEGRASE INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIREMIA; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIGENS, CD27; ANTIGENS, CD31; ANTIGENS, CD38; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MIDDLE AGED; PYRROLIDINONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 84855176017     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283509826     Document Type: Article

References (34)

1. Barreiro P, Soriano V, Casas E, González-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or nonnucleosides. AIDS 2002; 16:245-249.
2. Sempowski G, Haynes B. Immune reconstitution in patients with HIV infection. Annu Rev Med 2002; 53:269-284.
3. Walker R, Carter C, Muul L, Natarajan V, Herpin B, Leitman S, et al. Peripheral expansion of preexisting mature T cells is an important means of CD4R T-cell regeneration HIV-infected adults. Nat Med 1998; 4:852-856.
4. Ye P, Kirschner D. Reevaluation of T cell receptor excision circles as a measure of human recent thymic emigrants. J Immunol 2002; 168:4968-4979.
5. Junge S, Kloeckener-Gruissem B, Zufferey R, Keisker A, Salgo B, Fauchere JC, et al. Correlation between recent thymic emigrants and CD31R (PECAM-1) CD4R T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol 2007; 37:3270-3280.
6. Kohler S, Thiel A. Life after the thymus: CD31R and CD31-human naive CD4R T-cell subsets. Blood 2009; 113:769-774.
7. Plana M, Garcia F, Darwich L, Romeu J, López A, Cabrera C, et al., Red de Investigación en Sida (RIS). The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. Immunology 2011; 133:318-328.
8. Badley A, Pilon A, Landay A, Lynch D. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96:2951-2964.
9. Dyrhol-Riise A, Stent G, Røsok B, Voltersvik P, Olofsson J, Asjö B. The Fas/FasL system and T cell apoptosis in HIV-1-infected lymphoid tissue during highly active antiretroviral therapy. Clin Immunol 2001; 101:169-179.
10. Herbeuval J, ShearerG.HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007; 123:121-128.
11. Benito JM, López M, Martín JC, Lozano S, Martínez P, Gonzá-lez-Lahoz J, et al. Differences in cellular activation and apop-tosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2002; 18:1379-1388.
12. FDA notifications. Accelerated approval for raltegravir tablets. AIDS Alert 2007; 22:143-144.
13. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009; 24:106-107.
14. Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
15. Rockstroh J, Lennox J, De Jesus E, Saag M, Lazzarin A, Wan H, et al., STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive HIV-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53:807-816.
16. Eron J, Young B, Cooper D, Youle M, Dejesus E, Andrade-Villanueva J, et al., SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopi-navir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multi-centre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
17. Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al., SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697-1707.
18. Vispo E, Barreiro P, Maida I, Mena A, Blanco F, Rodríguez-Novoa S, et al. Simplification from protease inhibitors to once-or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010; 11:197-204.
19. Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello A, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25:1481-1487.
20. Pakker N, Notermans D, de Boer R, Roos M, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-214.
21. Poulin J, Viswanathan M, Harris J, Komanduri K, Wieder E, Ringuette N, et al. Direct evidence for thymic function in adult humans. J Exp Med 1999; 190:479-486.
22. Asmuth D, Goodrich J, Cooper D, Haubrich R, Rajicic N, Hirschel B, et al. CD4R T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 54:394-397.
23. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4R cell rises in HIV-infected patients. PLoS One 2010; 5:e13188.
24. Du D, Volpe D, Grieshaber C, Murphy M. In vitro toxicity of 3-azido-3-deoxythymidine, carbovir and 2-,3-didehydro-2-,3-ideoxythymidine to human and murine haematopoietic progenitor cells. Br J Haematol 1992; 80:437-445.
25. Gandhi R, Zheng L, Bosch R, Chan E, Margolis D, Read S, et al. AIDS Clinical Trials Group A5244 team. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
26. Hatano H, Hayes T, Dahl V, Sinclair E, Lee T, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4R T cell response. J Infect Dis 2011; 203:960-968.
27. Buzón M, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas M, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
28. Benito JM, López M, Lozano S, Ballesteros C, Martínez P, González-Lahoz J, et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4RT cells under successful highly active antirretro-viral therapy. J Acquir Immune Defic Syndr 2005; 38:373-381.
29. Dianzani U, Funaro A, DiFranco D, Garbarino G, Bragardo M, Redoglia V, et al. Interaction between endothelium and CD4RCD45RAR lymphocytes. Role of the human CD38 molecule. J Immunol 1994; 153:952-959.
30. Clement L, Vink P, Bradley G. Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4R cells in the human neonate. J Immunol 1990; 145:102-108.
31. Rabian-Herzog C, Lesage S, Gluckman E. Characterization of lymphocyte subpopulations in cord blood. Bone Marrow Transplant 1992; 9 (Suppl 1):64-67.
32. BofillM, AkbarA, Salmon M, Robinson M, BufordG, Janossy G. Immature CD45RA(low)RO(low) T cells in the human cord blood. I.Antecedents of CD45RAR unprimedT cells. J Immunol 1994; 152:5613-5623.
33. Deaglio S, Morra M, Mallone R, Ausiello C, Prager E, Garbarino G, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160:395-402.
34. Corbeau P, Reynes J. Immune reconstitution under antiretro-viral therapy: the new challenge in HIV-1 infection. Blood 2011; 117:5582-5590.